PubMed
Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295
Teichman et al., 2006
GH SecretagoguesCompoundableB
CJC-1295
CJC-1295 DAC
CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- B
- Experience
- 98
- Activity
- 78
Overall check-ins
Trackers & reports
Overview
About CJC-1295
CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.
- Category
- GH Secretagogues
- Regulatory status
- Compoundable
- Also known as
- CJC-1295 DAC
- Self-reports
- 33
Community
What 33 users report
33 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 96% · Mixed 4% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
138
Sleep
138
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Fatigue
2
Headache
2
Water retention
1
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.1–3 mg
0.1–0.2 mg
24
0.2–0.4 mg
39
0.4–0.6 mg
23
1–2 mg
31
2–3 mg
21
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 48 days · Based on 25 repeat reporters
Research
Cited research (3)
Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
ClinicalTrials.gov
CJC-1295 growth hormone studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
Tools
Explore more
Explore
More ways to learn about CJC-1295 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about CJC-1295?
This page summarizes 33 anonymized self-reports from PeptIQ users who track CJC-1295, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for CJC-1295?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for CJC-1295?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is CJC-1295 safe to use?
This wiki does not assess safety or recommend use. CJC-1295 is listed as Compoundable. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of CJC-1295?
This wiki summarizes observational community reports and linked citations for CJC-1295. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for CJC-1295 for study-level context — not medical advice.
What is the legal status of CJC-1295?
CJC-1295 is listed in PeptIQ as Compoundable. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of CJC-1295?
Safety data quality for CJC-1295 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on CJC-1295?
This page links 3 indexed sources for CJC-1295. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.